AR026355A1 - Formulacion y metodo antidiabetico. - Google Patents

Formulacion y metodo antidiabetico.

Info

Publication number
AR026355A1
AR026355A1 ARP000105804A ARP000105804A AR026355A1 AR 026355 A1 AR026355 A1 AR 026355A1 AR P000105804 A ARP000105804 A AR P000105804A AR P000105804 A ARP000105804 A AR P000105804A AR 026355 A1 AR026355 A1 AR 026355A1
Authority
AR
Argentina
Prior art keywords
diabetes
treatment
antidiabetic
patients
drug
Prior art date
Application number
ARP000105804A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23716278&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR026355(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR026355A1 publication Critical patent/AR026355A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporciona una formulacion farmacéutica antidiabética de bajas dosis especialmente adaptada para el tratamiento de la diabetes de Tipo II en pacientessin experiencia en el fármaco, que incluye una combinacioan de metformina (empleada en una canti dad reducida (menos de 800 mg de metformina por día) comparacon al que se emplea en la práctica médica generalmente aceptada) y al menos algun otro agente antidiabético tal como una sulfonil urea, por ejemplo, gliburidacuya combinacion proporciona al menos alrededor de una eficacia sustancialmente equivalente en el tratamiento de la diabetes en pacientes sin experiencia en elfármaco, como las formulaciones antidiabéticas hechas que contienen metformina empleada en dosis prescritas en la práctica médica generalmente aceptada paraterapia de primera línea para el tratamiento de la diabetes, pero con efectos laterales sustancialemente reducidos, tales como hipoglicemia y/ogastrointestinal. Un método para el tratamiento de la diabetes en pacien tes sin exeriencia en el fármaco también se proporciona empleando la formulacionanterior para reducir la resistencia a la insulina y/o la excursion de glucosa post-prandial y/o la hemoglobina 1 Ac, y/o el incremento de la insulina post-prandial, por ello trantando la diabetes.
ARP000105804A 1999-11-03 2000-11-03 Formulacion y metodo antidiabetico. AR026355A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method

Publications (1)

Publication Number Publication Date
AR026355A1 true AR026355A1 (es) 2003-02-05

Family

ID=23716278

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105804A AR026355A1 (es) 1999-11-03 2000-11-03 Formulacion y metodo antidiabetico.

Country Status (34)

Country Link
US (2) US6586438B2 (es)
EP (1) EP1253944A2 (es)
JP (2) JP2003529551A (es)
KR (2) KR20020050253A (es)
CN (3) CN101273981B (es)
AR (1) AR026355A1 (es)
AU (1) AU781781B2 (es)
BG (2) BG106732A (es)
BR (1) BR0015295A (es)
CA (1) CA2389931A1 (es)
CZ (2) CZ20021547A3 (es)
DE (1) DE60038455T2 (es)
EE (1) EE05210B1 (es)
ES (1) ES2302702T3 (es)
GE (2) GEP20053539B (es)
HK (1) HK1045655A1 (es)
HU (1) HUP0300642A3 (es)
IL (3) IL149138A0 (es)
LT (1) LT5025B (es)
LV (1) LV12907B (es)
MX (1) MXPA02004290A (es)
MY (2) MY136636A (es)
NO (1) NO20022086L (es)
NZ (1) NZ552074A (es)
PL (1) PL366112A1 (es)
RO (1) RO123109B1 (es)
RU (1) RU2276604C2 (es)
SK (1) SK4992002A3 (es)
TN (2) TNSN00206A1 (es)
TW (1) TWI241185B (es)
UA (2) UA76706C2 (es)
UY (1) UY26425A1 (es)
WO (1) WO2001032158A2 (es)
ZA (2) ZA200203367B (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20030040469A1 (en) * 2000-03-08 2003-02-27 Knudsen Liselotte Bjerre Lowering serum lipids
RU2281764C2 (ru) * 2000-03-17 2006-08-20 Адзиномото Ко., Инк. Лекарственные средства для лечения осложнений, связанных с диабетом, и невропатии и их применения
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US7062312B2 (en) * 2001-01-17 2006-06-13 Pediamed Pharmaceuticals, Inc. Combination and method including a visual marker for determining compliance with a medication regimen
US20030022816A1 (en) * 2001-03-07 2003-01-30 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20020187926A1 (en) * 2001-03-07 2002-12-12 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
CA2461693A1 (en) * 2001-09-28 2003-04-03 Sun Pharmaceutical Industries Limited Dosage form for treatment of diabetes mellitus
US6924311B2 (en) * 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
US9045438B2 (en) 2002-01-25 2015-06-02 Silanes S.A. De C.V. Pharmaceutical composition containing glimepiride and metformin hydrochloride
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
ES2327328T3 (es) * 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
JP2004067575A (ja) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SE526943C2 (sv) * 2002-08-26 2005-11-22 Indevex Ab Födoämneskompositionsprodukt
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
ATE457166T1 (de) * 2003-07-24 2010-02-15 Wockhardt Ltd Orale zusammensetzungen zur behandlung von diabetes
WO2005012346A1 (en) * 2003-07-25 2005-02-10 Conjuchem, Inc. Long lasting insulin derivatives and methods thereof
US20050202063A1 (en) * 2003-08-26 2005-09-15 Ebn International Kft Food product
EP1732513A2 (en) * 2003-12-31 2006-12-20 Alpharma, Inc. Rosiglitazone formulations
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
EP1746993A4 (en) * 2004-04-29 2007-08-29 Andrx Labs Llc METFORMIN COMPOSITIONS WITH CONTROLLED RELEASE
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
WO2006074278A2 (en) * 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd COMBINED MEDICINE FOR THE TREATMENT OF DIABETES
AU2006326658A1 (en) * 2005-12-09 2007-06-21 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
GEP20105033B (en) * 2005-12-28 2010-06-25 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2873524C (en) 2006-05-04 2018-02-20 Boehringer Ingelheim International Gmbh A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
WO2008011713A1 (en) * 2006-07-26 2008-01-31 Diamedica Inc. Methods of diagnosis and treatment for metabolic disorders
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20100136561A1 (en) * 2008-05-16 2010-06-03 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101189639B1 (ko) * 2008-12-15 2012-10-12 씨제이제일제당 (주) 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
ES2811342T3 (es) 2009-03-31 2021-03-11 Ligand Pharm Inc Antagonista de receptores de endotelina y angiotensina II de bifenilsulfonamida para tratar glomeruloesclerosis y nefropatía inducida por IgA
WO2010127103A1 (en) 2009-04-29 2010-11-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
US8455472B2 (en) 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
CN101810628B (zh) * 2010-04-13 2012-05-23 北京四环科宝制药有限公司 二甲双胍格列吡嗪片及其制备方法
NZ603169A (en) 2010-04-27 2015-02-27 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
JP6227406B2 (ja) 2010-05-11 2017-11-08 ヤンセン ファーマシューティカ エヌ．ベー． ＳＧＬＴの阻害剤としての１−（β−Ｄ−グルコピラノシル）−２−チエニル−メチルベンゼン誘導体を含有する医薬製剤
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
NZ727980A (en) 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012090225A2 (en) * 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
MX2013007884A (es) 2011-01-07 2013-09-13 Elcelyx Therapeutics Inc Terapias a base de ligando del receptor quimiosensorial.
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
CN104144704B (zh) 2011-11-03 2018-03-23 西兰制药公司 Glp‑1受体激动剂肽胃泌素缀合物
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2012363873B2 (en) 2012-01-06 2017-11-23 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
CN110693867A (zh) 2012-01-06 2020-01-17 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
WO2013115742A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Pharmaceutical composition comprising alpha-glucosidase inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
LT2854841T (lt) 2012-06-04 2017-06-12 Diamedica Inc. Kalikreino 1 iš žmogaus audinio glikozilinimo izoformos
MX356957B (es) 2012-07-23 2018-06-20 Zealand Pharma As Analogos del glucagon.
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
KR101336499B1 (ko) * 2013-03-06 2013-12-03 씨제이제일제당 (주) 당뇨병의 예방 또는 치료용 복합 조성물
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
SG11201602965WA (en) 2013-10-17 2016-05-30 Zealand Pharma As Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
CN105849122B (zh) 2013-11-06 2021-04-30 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
CN107636010B (zh) 2015-04-16 2021-10-01 西兰制药公司 酰化胰高血糖素类似物
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
CN117384274A (zh) 2016-12-09 2024-01-12 西兰制药公司 酰化的glp-1/glp-2双重激动剂
EP3592377A4 (en) 2017-03-09 2021-02-17 Diamedica Inc. DOSAGE FORMS OF TISSUE KALLIKREIN 1
JP2022502373A (ja) * 2018-09-24 2022-01-11 ペンデュラム セラピューティクス， インコーポレイテッド 微生物組成物および使用方法
WO2020068163A1 (en) 2018-09-24 2020-04-02 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
CN113648318B (zh) * 2020-05-12 2023-08-25 中国科学院上海营养与健康研究所 增强细胞产热和治疗疾病的应用
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US4060634A (en) 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
DE2348334C2 (de) 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
EP0062704A1 (de) 1980-12-03 1982-10-20 Hoechst Aktiengesellschaft Cyclopropancarbonsäureester-derivate als Mittel zum Bekämpfen von Magendasseln bei Equiden
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4916163A (en) 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
AU729529B2 (en) * 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
ATE201139T1 (de) 1997-06-13 2001-06-15 Novo Nordisk As Neue dosierung für diabetes type 2
CZ298469B6 (cs) 1997-06-18 2007-10-10 Smithkline Beecham Plc Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
KR20010024533A (ko) 1997-10-17 2001-03-26 오흘러 로스 제이. 퀴놀린 유도체의 치료적 용도
CA2312990C (en) 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
FR2774591B1 (fr) 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
FI111167B (fi) * 1998-02-24 2003-06-13 Kemira Chemicals Oy Menetelmä lietteen säilyvyyden parantamiseksi
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
ATE250418T1 (de) 1998-07-15 2003-10-15 Merck Sante Sas Tabletten enthaltend eine kombination von glibenclamid und metformin
JP2002524517A (ja) 1998-09-17 2002-08-06 ブリストル−マイヤーズ スクイブ カンパニー ａＰ２阻害剤およびその組成物を用いる糖尿病の治療方法
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
ZA200203367B (en) 2003-09-10
WO2001032158A2 (en) 2001-05-10
WO2001032158A3 (en) 2002-08-29
CZ20021547A3 (cs) 2003-01-15
ES2302702T3 (es) 2008-08-01
RU2002113764A (ru) 2004-03-20
LT5025B (lt) 2003-06-25
CN100386114C (zh) 2008-05-07
TNSN00206A1 (en) 2005-11-10
DE60038455T2 (de) 2009-04-23
IL149138A0 (en) 2002-11-10
CZ304090B6 (cs) 2013-10-16
GEP20053538B (en) 2005-06-10
CN101273981A (zh) 2008-10-01
UY26425A1 (es) 2001-07-31
IL149138A (en) 2007-12-03
LT2002062A (en) 2003-03-25
UA75583C2 (uk) 2006-05-15
US6586438B2 (en) 2003-07-01
PL366112A1 (en) 2005-01-24
UA76706C2 (uk) 2006-09-15
GEP20053539B (en) 2005-06-10
EE200200241A (et) 2003-12-15
US20020183345A1 (en) 2002-12-05
HUP0300642A2 (hu) 2003-07-28
HUP0300642A3 (en) 2006-05-29
SK4992002A3 (en) 2003-04-01
ZA200203368B (en) 2003-09-02
LV12907B (en) 2003-08-20
TWI241185B (en) 2005-10-11
BG106732A (bg) 2003-02-28
BG65850B1 (bg) 2010-03-31
BG106733A (bg) 2003-02-28
KR20020057994A (ko) 2002-07-12
MXPA02004290A (es) 2003-02-12
RU2276604C2 (ru) 2006-05-20
US7598262B2 (en) 2009-10-06
DE60038455D1 (de) 2008-05-08
KR20020050253A (ko) 2002-06-26
NO20022086L (no) 2002-06-24
EE05210B1 (et) 2009-10-15
TNSN00207A1 (en) 2005-11-10
AU781781B2 (en) 2005-06-16
MY136636A (en) 2008-11-28
JP2003529551A (ja) 2003-10-07
NZ552074A (en) 2008-06-30
US20020177602A1 (en) 2002-11-28
BR0015295A (pt) 2003-06-24
HK1045655A1 (zh) 2002-12-06
KR100769786B1 (ko) 2007-10-24
JP2013028631A (ja) 2013-02-07
NO20022086D0 (no) 2002-05-02
CN102283853A (zh) 2011-12-21
CN101273981B (zh) 2011-01-26
CA2389931A1 (en) 2001-05-10
IL149139A (en) 2011-11-30
RO123109B1 (ro) 2010-11-30
MY125118A (en) 2006-07-31
AU8022900A (en) 2001-05-14
EP1253944A2 (en) 2002-11-06
CN1414862A (zh) 2003-04-30

Similar Documents

Publication Publication Date Title
AR026355A1 (es) Formulacion y metodo antidiabetico.
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
EP1379232B1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
JP2018138578A5 (es)
US7575757B2 (en) Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
BR112013005907B1 (pt) Composição farmacêutica parenteral
AR026356A1 (es) Metodo para tratar la diabetes
AR047779A1 (es) Composiciones y metodos para tratar diabetes
EP2635269B1 (en) A combination composition
McKinney et al. Reversal of severe tricyclic antidepressant-induced cardiotoxicity with intravenous hypertonic saline solution
US20060257388A1 (en) Drug delivery systems for stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
KR880005933A (ko) 비타민 b6-함유 약제학적 제제
MXPA04007183A (es) Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2.
RU2543635C2 (ru) Способ и фармацевтические композиции для лечения постпрандиальной гипергликемии диабета ii типа введением через слизистую ротовой полости
JP2002510645A5 (es)
CA2489526C (en) Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof
Kadhe et al. Advances in drug delivery of oral hypoglycemic agents
CA2450915A1 (en) Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
Saravu et al. Near-fatal amlodipine poisoning.
Joshi et al. Designer insulins regimens in clinical practice-pilot multicenter Indian study
JP2001316293A5 (es)
Trifu et al. Modern aspects regardind the use of local anesthetic medicines in dermatologic surgery
RU2023129893A (ru) Фармацевтическая композиция для профилактики или лечения сахарного диабета у животного семейства псовые, содержащая энавоглифлозин
JP2009526819A (ja) 塩酸プリロカインを有する新規の高比重組成物、この新規の組成物の髄腔内麻酔への使用、及びこの組成物の製造方法

Legal Events

Date Code Title Description
FB Suspension of granting procedure